



Published in final edited form as:

Headache. 2018 March ; 58(3): 371–380. doi:10.1111/head.13235.

## Association between migraine and suicidal behaviors: a nationwide study in the U.S.A

Lauren E. Friedman, Ph.D.<sup>1</sup>, Qiu-Yue Zhong, M.D., Sc.M.<sup>1</sup>, Bizu Gelaye, Ph.D. M.P.H.<sup>1</sup>, Michelle A. Williams, Sc.D.<sup>1</sup>, and B. Lee Peterlin, D.O.<sup>2</sup>

<sup>1</sup>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA

<sup>2</sup>Johns Hopkins School of Medicine Neurology, Baltimore, MD, USA

### Abstract

**Background**—Recent studies show migraineurs are at an increased risk of developing suicidal behaviors, even after controlling for comorbid depression. However, previous research has not examined the impact of psychiatric mood disorders on suicidal behaviors in migraineurs within a nationally representative sample.

**Objective**—A cross-sectional study was used to investigate the association between migraine and suicidal behaviors and determine whether psychiatric comorbidities modify this association in a nationwide inpatient cohort.

**Methods**—We analyzed the Nationwide Inpatient Sample of hospitalizations compiled from USA billing data. Migraine, suicidal behaviors, and psychiatric disorders were identified based on the International Classification of Diseases, 9<sup>th</sup> Revision, Clinical Modification diagnosis codes from hospitalization discharges (2007–2012). Weighted national estimates were used to estimate odds ratios (OR) and 95% confidence intervals (CI).

**Results**—156,172,826 hospitalizations were included, of which 1.4% had a migraine diagnosis and 1.6% had a diagnosis of suicidal behavior. Migraineurs had a 2.07-fold increased odds of suicidal behaviors (95% CI: 1.96–2.19) compared with non-migraineurs. We repeated analyses after stratifying by depression, anxiety, or posttraumatic stress disorder (PTSD). Among hospitalizations with depression, migraine was associated with a 20% reduced odds of suicidal behaviors (95% CI: 0.76–0.85). Among hospitalizations without depression, migraine was associated with 2.35-fold increased odds of suicidal behaviors (95% CI: 2.20–2.51). In stratified analyses, we noted that among hospitalizations with anxiety, migraineurs had slightly increased odds of suicidal behaviors (OR: 1.07, 95% CI: 1.02–1.13). Among hospitalizations without anxiety, migraine was associated with a 2.06-fold increased odds of suicidal behaviors (95% CI: 1.94–2.20). Similarly, in analyses stratified by PTSD, migraine was not associated with an increased risk of suicidal behaviors (OR: 1.00, 95% CI: 0.94–1.07) among those with PTSD.

**Corresponding Author:** Lauren E. Friedman, Ph.D., Department of Epidemiology, Harvard T. H. Chan School of Public Health, 677 Huntington Ave, K501, Boston, MA 02115, USA., Tel: 617-432-2289, Fax: 617-566-7805, lfriedm@hsph.harvard.edu.

**Conflict of interest statement:** The other authors have no conflicts of interest to disclose.

**Authors' contributions:** LEF, BLP, BG, and MAW conceived and designed the study. QYZ analyzed data and LEF drafted the manuscript. All authors interpreted the data, critically revised the draft for important intellectual content, and gave final approval of the manuscript to be published.

However, the odds of suicidal behaviors were increased among hospitalizations without PTSD (OR: 1.95, 95%CI: 1.84–2.08).

**Conclusion**—Chronic conditions that do not affect the current hospitalization may not have been reported. The presence of psychiatric diagnoses influences associations of suicidal behaviors with migraine in a national inpatient sample. Migraineurs with diagnosed comorbid psychiatric disorders may be receiving care that mitigates their risk for suicidal behaviors.

### Keywords

migraine; suicidal behaviors; posttraumatic stress disorder; depression; anxiety

---

## Introduction

Migraine affects approximately 12% of the general population<sup>1, 2</sup>. An extensive body of literature has demonstrated that migraine is comorbid with several psychiatric disorders including depression, anxiety, and posttraumatic stress disorder (PTSD)<sup>3–6</sup>. Further, recent data support that even after controlling for comorbid depression, migraineurs are at an increased risk of developing suicidal behaviors<sup>7, 8</sup>. Suicidal behaviors include suicidal ideation, suicide plans, and suicidal attempts<sup>9</sup>. The strongest predictors of completed suicide include depression and suicidal behaviors<sup>10, 11</sup>. Thus, examining individuals more likely to exhibit suicidal behaviors is important for identifying those at highest risk of suicide. Further, targeted interventions to prevent suicide should focus on those most likely to develop suicidal behaviors.

While two studies have examined suicide in migraineurs<sup>12, 13</sup>, few studies have examined suicidal behaviors (e.g. suicidal ideation, suicide attempts). All of these studies have been relatively small or examined the association in targeted populations, i.e. pregnant women<sup>14</sup>, adolescents<sup>15–17</sup> and young adults<sup>4, 18</sup>. Previous cohorts have included clinic<sup>14</sup> and community based<sup>4, 15, 16, 18</sup> samples. To our knowledge, the only previous nationally-representative population based study was done in a population of adolescents<sup>17</sup>. None have examined the association among a nationally representative adult hospital inpatient database sample or the impact of psychiatric mood disorders on the risk of suicidal behaviors in those with migraine. Therefore, our study was designed to examine the association between migraine and suicidal behaviors and the impact of comorbid mood (depression, anxiety) and stress (PTSD) disorders on this association among a nationally representative sample of adult inpatients from 2007 to 2012 in the USA.

## Methods

### Study Sample

Our study included adult participants, 18 years of age or older, with hospital discharges in 2007–2012 from the Nationwide Inpatient Sample (NIS) database. The NIS is a database of hospital inpatient stays compiled from billing data across the USA as part of the Healthcare Cost and Utilization Project (HCUP). The HCUP is the largest inpatient healthcare utilization database in the USA and includes approximately 20% of discharges from all nonfederal, acute care hospitals. All hospitals participating in HCUP are included in the

sample. Hospital characteristics, including geographic region, ownership, location, teaching status, and bed size, were used for weighting to account for the survey structure and to create a sample that is representative of U.S. hospital admissions<sup>19, 20</sup>.

### **Standard Protocol Approvals, Registrations, and Patient Consents**

As the NIS data are publicly available and do not contain personal identifiers, this study was exempt from review by the Office of Human Research Administration at the Harvard T.H. Chan School of Public Health, Boston, MA.

### **Demographic Characteristics**

Sociodemographic variables including age, sex, race, median household income quartiles, length of stay, and total hospital charges were evaluated. Smoking was identified using International Classification of Diseases, 9<sup>th</sup> Revision, Clinical Modification (ICD-9-CM) diagnosis codes (305.1X, 649.0X, and V15.82).

### **Migraine**

Adult onset migraine diagnoses were based on the ICD-9-CM diagnosis codes (346. XX). Hospitalizations without migraine were composed of hospitalizations without a diagnosis of migraine (ICD-9-CM: 346.XX), tension-type headache (ICD-9-CM: 307.81), and headache (ICD-9-CM: 784.0X and 339.XX)<sup>21</sup>.

### **Suicidal behaviors**

Suicidal behaviors were characterized based on ICD-9-CM diagnosis codes and were used to identify hospitalizations with suicidal behaviors, including suicidal ideation (V62.84) and suicide and self-inflicted injury (E950.XX-E959.XX). We did not utilize datasets prior to 2007 as the diagnosis code for suicidal ideation were not used prior to October 2005.

### **Psychiatric disorders**

ICD-9-CM diagnosis codes were used to diagnose psychiatric disorders, including non-psychotic depression (296.82, 301.12, 309.28, 296.2X, 296.3X, 300.4X, 309.0X, 309.1X, 311.XX), anxiety (300.00, 300.01, 300.02, 300.21, 300.22, 300.23, 300.29, 309.21, 300.81, 300.2X, 300.3X, 300.7X, 308.2X, 308.3X), posttraumatic stress disorder (PTSD; 309.81), alcohol or substance abuse (291.XX, 292.XX, 303.XX, 304.XX, 305.XX, 648.3X, 655.5X, 965.0X, V65.42), psychosis (295.XX, 296.XX, 297.XX, 298.XX), and any psychiatric disorder from NIS hospitalization records<sup>22</sup> (Supplementary Table 1).

### **Statistical Analysis**

Our primary unit of analysis was per hospitalization. Repeated hospital discharges are not linked in the NIS database, therefore a patient who was admitted to the hospital multiple times in one year would be counted each time as a separate hospitalization. In all analyses, we used discharge-level sampling weights based on the sampling scheme and provided by the datasets to report national estimates from all USA community hospitals. Adjusted discharge-level sampling weights were applied to each year and the estimates for each year were then merged. We compared the distributions of sociodemographic, psychiatric

characteristics, and hospital characteristics between hospitalizations with and without migraine by performing Wald Chi-square and *t*-tests. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariable logistic regressions. We also calculated adjusted ORs and 95% CIs with *a priori* confounders including age (continuous), race/ethnicity, median household income quartiles for patient zip code, hospital region (Northeast, Midwest, South, West), hospital location (rural or urban), year, and age-adjusted Charlson Comorbidity Index, which assigns disease weights. Diseases with a weight of one include myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, ulcer disease, mild liver disease, and diabetes, and diseases with a weight of 2 include diabetes with end organ damage, any tumor, leukemia, and lymphoma. Moderate or severe liver disease has a weight of three, and metastatic solid tumor and AIDS have a weight of six. All variables had < 5% missing data except for race/ethnicity. We created missing indicator variables to address missing data for race/ethnicity and median household income quartiles. Total hospitalization charges were adjusted for inflation to reflect 2012 US dollars<sup>23</sup>. An age-unadjusted Charlson Comorbidity Index was calculated by adding separate disease weights, with a Charlson Comorbidity Index score of 0 as the lowest risk attributable to comorbid disease. For calculating an age-adjusted Charlson Comorbid Index, a patient aged 40 years old is assumed to have the lowest risk of comorbid death attributable to age and each decade of age over 40 adds 1 point to risk (e.g. 50–59 years, 1 point; 60–69 years, 2 points; 70–79 years, 3 points). These points for age are added to the score from the age-adjusted Charlson Comorbidity Index (e.g., 0, 1, 2, 3, etc.)<sup>24–26</sup>. Prior studies have reported migraine is modified by age<sup>27</sup> and sex<sup>28</sup>. Given this, we repeated the primary analysis stratifying by age categories (<50 vs. 50 years old) and sex (male vs. female; Supplementary Table 3). Given previous studies have shown psychiatric comorbidities modify the association between migraine and suicidal behaviors<sup>3–7</sup>, we repeated the analyses after stratifying participants according to depression, anxiety, or PTSD, respectively. We performed analyses for suicidal ideation and suicide and self-inflicted injury separately and the associations of migraine with suicidal ideation/suicide and self-inflicted injury were similar (data not shown).

All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA) and SAS-callable SUDAAN software (version 11.0.1, RTI International, Research Triangle, NC, USA). Statistical significance was set at two-sided  $P < 0.05$ . Computations were run on the Odyssey cluster supported by the Faculty of Arts & Sciences Division of Science, Research Computing Group at Harvard University.

## Results

Sociodemographics are presented in Table 1 and hospital characteristics in Supplementary Table 2. A total of 156,172,826 hospitalizations with a mean age of 57.2 years (Standard Error, SE = 0.1 years) were included. The majority of hospitalizations were female (59.9%), 50 years of age or older (63.7%), and had a self-identified race of white (57.4%). A total of 11.5% of hospitalizations had non-psychotic depression, 4.9% had anxiety, and 0.54% had PTSD. The majority of hospitalizations (63.8%) had 2 or more comorbidities as measured by the age-adjusted Charlson Comorbidity Index. 1.4% of all hospitalizations had migraine. As compared to those without migraine, migraineurs were more likely to be less than 50

years old, female, smokers, and self-identify as white ( $P<0.0001$ ). Migraineurs were also more likely to have depression, anxiety, or PTSD ( $P<0.0001$ ) than those without migraine. Those with migraine were more likely to have 2 comorbid conditions than non-migraineurs ( $P<0.0001$ ; Table 1).

Hospitalizations with migraine had statistically significantly increased odds of suicidal behaviors (OR: 2.69; 95%CI: 2.55–2.86; Table 2). After adjusting for confounders (including age, sex, race, median household income quartiles for patient zip code, hospital location, hospital region, year, and age-adjusted Charlson Comorbidity Index), migraineurs had a 2.07-fold increased odds of suicidal behaviors (95%CI: 1.96–2.19; Table 2). Compared to non-migraineurs, migraineurs less than 50 years old had a 2.01-fold increased odds of suicidal behaviors (95%CI: 1.91–2.12), and migraineurs 50 years old had a 1.66-fold increased odds of suicidal behaviors (95%CI: 1.52–1.80; Supplementary Table 3). Among women, the association followed a similar pattern (migraineurs <50 years: OR: 2.25, 95%CI: 2.13–2.37; migraineurs 50 years: OR: 1.60, 95%CI: 1.48–1.72). Among men, migraineurs <50 years had 1.20-fold increased odds of suicidal behaviors (95%CI: 1.10–1.30), and older migraineurs had a 1.68-fold increased odds of suicidal behaviors compared to non-migraineurs (95%CI: 1.43–1.98; Supplementary Table 3).

We repeated the analyses after stratifying hospitalizations according to depression, anxiety, or PTSD, respectively (Table 2). In a stratified analysis among hospitalizations with depression, migraineurs had 20% reduced odds of suicidal behaviors after adjusting for confounders (OR: 0.80, 95%CI: 0.76–0.85). Among those without depression, migraineurs had a 2.35-fold increased odds of comorbid suicidal behaviors (95%CI: 2.20–2.51) after adjusting for sociodemographic characteristics and comorbidities. In a stratified analysis, we noted that among hospitalizations with diagnosed anxiety, migraineurs had 1.07-fold increased odds of suicidal behaviors after adjusting for confounders (95%CI: 1.02–1.13). Among those without anxiety, migraineurs had a 2.06-fold increased odds of comorbid suicidal behaviors (95%CI: 1.94–2.20) after adjusting for confounders. Similarly, in analyses stratified by PTSD status, migraine was not associated with suicidal behaviors (OR: 1.00, 95%CI: 0.94–1.07) among hospitalizations with diagnosed PTSD. However, among hospitalizations without a diagnosis of PTSD, migraine was associated with a 1.95-fold increased odds of suicidal behaviors (95%CI: 1.84–2.08; Table 2).

## Discussion

In our study, migraineurs are significantly more likely to have psychiatric disorders, including depression, anxiety, and PTSD than those without migraine. Compared to hospitalizations without migraine, migraineurs had a 2.07-fold increased odds of suicidal behaviors (95%CI: 1.96–2.19). This is comparable to previous studies on the association between migraine and suicidal behaviors, including suicidal ideation and suicide attempts. A recent meta-analysis of 148,977 participants from six studies evaluating the association between migraine and suicidal ideation found a 31% increased odds of suicidal ideation among migraineurs (95%CI: 1.10–1.55) compared with non-migraineurs<sup>7</sup>. In a large Health Maintenance Organization in Michigan, Breslau *et al.* found 2.7-fold increased odds of suicide attempts among participants with migraine and *without* major depression (migraine

without aura: OR: 2.7, 95%CI: 0.7–9.5; migraine with aura: OR: 4.3, 95%CI: 1.2–15.7). Among participants *with* both migraine and major depression, there was an association between migraine and suicide attempts (migraine without aura: OR: 10.9, 95%CI: 3.1–38.6; migraine with aura: OR: 23.2, 95%CI: 8.4–63.8)<sup>18</sup>. In a subsequent longitudinal study, Breslau *et al.* found a 4.43-fold increased odds of suicide attempts among migraineurs as compared to those with no headache history (95%CI: 1.93–10.2)<sup>29</sup>.

Our study used ICD-9-CM diagnosis codes to identify hospitalizations with suicidal behaviors. Two previous studies used ICD diagnosis codes to investigate the association between migraine and suicidal behaviors and found similar results. Singhal *et al.* examined associations between chronic illnesses and self-harm (ICD-9 codes E950–E959 and ICD-10 codes X60–X64, X66–X84) and a certified cause of death from suicide (ICD-9 codes 9 E950–E959 and ICD-10 X60–X84). Specifically, among migraineurs there was a reported increased risk of self-harm (rate ratio [RR]: 1.8, 95%CI: 1.7–1.8) and death from suicide (RR: 1.3, 95%CI: 1.0–1.8)<sup>13</sup>. Similarly, Ilgen *et al.* showed an association between migraine and suicide death after controlling for comorbid psychiatric disorders (hazard ratio: 1.34, 99%CI: 1.02–1.77)<sup>12</sup>. Taken together, migraineurs have an increased risk of suicidal behaviors.

In separate analyses performed within strata defined by psychiatric diagnosis, migraineurs without diagnosed depression, anxiety, or PTSD had increased odds of suicidal behaviors (Table 2). Conversely, migraineurs with depression, anxiety, or PTSD diagnoses had reduced or similar odds of suicidal behaviors compared to non-migraineurs with comorbid psychiatric disorder. It is also possible that migraineurs with diagnosed comorbid psychiatric disorders are receiving additional care that may mitigate their risk for suicidal behaviors. In a longitudinal cohort study among migraineurs, a decrease in headache frequency and intensity was associated with decreased depression symptoms after prophylactic treatment<sup>30</sup>. Comorbid anxiety and depression do not influence the medications taken by migraineurs; however, they do influence perceived treatment efficacy and satisfaction<sup>31</sup>. Antidepressant medications have also been shown to be effective in treating migraine and depressive symptoms concurrently, as well as migraine with concurrent anxiety<sup>32, 33</sup>. Migraine chronicity and previously diagnosed disorders may also effect whether individuals sought out medicine or other treatment options and may influence the effects that we see in participants with comorbid depression, anxiety or PTSD. Psychological factors, including anxiety, depression, and anger may also influence headache development, headache pain intensity, and response to treatments<sup>34</sup>. In a study of Brazilian women, migraineurs were more likely to report widespread chronic pain. Additionally, women with either depression or chronic migraines were more likely to report lower scores on the health-related quality of life index<sup>35</sup>. It has also been suggested that although migraine and depression are distinct disorders, migraineurs with comorbid depression may be a genetically unique subset of patients<sup>36</sup>. Patients with more severe depression are at an increased risk of chronic migraine onset. Among participants in the American Migraine Prevalence and Prevention (AMPP) study, the risk of transformation from episodic to chronic migraine increased in a dose-dependent way with depression severity<sup>37</sup>. Additionally, previous studies show that untreated migraines may hinder the remission of depression. In a longitudinal study of

patients with depression and no pharmacotherapy, comorbid migraine was associated with significantly more anxiety and somatic symptoms, and lower remission rates<sup>38</sup>.

The strengths of our study include the use of a large sample size and a nationally-representative population. Despite these strengths, our study has limitations. Suicidal behaviors were classified based on hospital administrative codes; therefore, we cannot distinguish between suicidal ideation, suicidal attempts, and non-suicidal self-inflicted injuries. This may potentially lead to misclassification of suicidal behaviors. Additionally, the use of hospital administrative codes lacks temporal information about these diagnoses and relevant clinical context. ICD-9 codes are collected for billing purposes and rely on accurate discharge coding of medical conditions. Baseline chronic conditions may not be reported if they do not affect current care or reasons for hospitalization, which would result in underestimations of the prevalence of suicidal behaviors and comorbid mood and stress disorders. The under diagnosis of chronic conditions, including migraine, is likely to be non-differential between groups and lead to an attenuation of reported odds ratios towards the null<sup>39</sup>. Furthermore, we did not distinguish between migraine sub-types (with aura vs. without aura), as the coding error for migraine subtypes is higher than the error for migraine<sup>40</sup>. Chronic migraineurs report significantly more emergency department visits and hospitalizations than episodic migraineurs in some studies<sup>41</sup> but not all<sup>42, 43</sup>. Suicidal behaviors among individuals with migraine with aura are consistently higher compared to migraine without aura patients<sup>4, 15, 16, 18, 29</sup>. Suicidal behaviors are most likely underreported due to stigmas associated with psychiatric conditions, which may make our estimates of the comorbidity of migraine and suicidal behaviors more conservative. Our study also may have unmeasured confounding associated with additional risk factors for suicidal behaviors that were not investigated. For example, physical pain conditions, including musculoskeletal, arthritis, fibromyalgia, abdominal, and pelvic pains have previously been associated with suicidal behaviors<sup>44, 45</sup>. Lastly, our use of a cohort of adult hospital inpatients warrants caution when generalizing to community based populations.

## Conclusions

Overall, migraine diagnosis was associated with increased odds of suicidal behaviors in a national inpatient sample. However, when analyses were performed within strata defined by psychiatric diagnosis, associations of migraine with suicidal behaviors were inverse or null among those with a diagnosis of depression, anxiety, or PTSD, respectively. It is possible that migraineurs with diagnosed comorbid psychiatric disorders are receiving care, including medication or therapy, that mitigates their risk for suicidal behaviors. Our study identifies high risk populations for suicidal behaviors, which should be further investigated for appropriate screening measures and targeted interventions. Future studies are needed to investigate the effects of comorbid psychiatric disorders, including depression, anxiety, and PTSD, on the association between migraine and suicidal behaviors. Our study highlights the importance of routine hospital screening and expanded research into treatment options for these comorbid conditions.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Dr. Gelaye has consulted for Egalet Corporation for unrelated project. Dr. Peterlin serves on the editorial boards for Headache and Neurology and has unrelated investigator-initiated grant support from Egalet Corporation and the Landenberger Foundation.

**Acknowledgements/Funding:** This research was supported by awards from the National Institutes of Health (NIH), National Institute of Minority Health and Health Disparities (T37-MD-001449) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01-HD-059835). The NIH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

## Abbreviations

<b>OR</b>	Odds Ratio
<b>CI</b>	Confidence Interval
<b>PTSD</b>	Posttraumatic Stress Disorder
<b>NIS</b>	Nationwide Inpatient Sample
<b>HCUP</b>	Healthcare Cost and Utilization Project
<b>ICD-9-CM</b>	International Classification of Diseases, 9 <sup>th</sup> Revision, Clinical Modification
<b>SE</b>	Standard Error

## References

1. Lipton R, Bigal M, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 2007; 68:343–349. [PubMed: 17261680]
2. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. *Headache*. 2015; 55:21–34. [PubMed: 25600719]
3. Peterlin BL, Rosso AL, Sheftell FD, Libon DJ, Mossey JM, Merikangas KR. Post-traumatic stress disorder, drug abuse and migraine: new findings from the National Comorbidity Survey Replication (NCS-R). *Cephalalgia*. 2011; 31:235–244. [PubMed: 20813779]
4. Breslau NDG, Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. *Psychiatry Res*. 1991; 37:11–23. [PubMed: 1862159]
5. Merikangas KRAJ, Isler H. Migraine and psychopathology. Results of the Zurich cohort study of young adults. *Arch Gen Psychiatry*. 1990; 47:849–853. [PubMed: 2393343]
6. Chai NC, Rosenberg JD, Lee Peterlin B. The epidemiology and comorbidities of migraine and tension-type headache. *Techniques in Regional Anesthesia and Pain Management*. 2012; 16:4–13.
7. Friedman LE, Gelaye B, Bain PA, Williams MA. A Systematic Review and Meta-analysis of Migraine and Suicidal Ideation. *Clin J Pain*. 2016
8. Novic A, Kolves K, O'Dwyer S, De Leo D. Migraine and Suicidal Behaviors: A Systematic Literature Review. *Clinical Journal of Pain*. 2016; 32:351–364. [PubMed: 26379072]
9. Nock M, Borges G, Bromet E, Cha C, Kessler R, Lee S. Suicide and suicidal behavior. *Epidemiologic Reviews*. 2008; 30:133–154. [PubMed: 18653727]



10. Nock, M., Nock, M., Borges, G., Ono, Y. Suicide: global perspectives from the WHO world mental health surveys. New York: Cambridge University Press; 2012.
11. Simon GE, Coleman KJ, Rossom RC, et al. Risk of suicide attempt and suicide death following completion of the Patient Health Questionnaire depression module in community practice. *J Clin Psychiatry*. 2016; 77:221–227. [PubMed: 26930521]
12. Ilgen M, Kleinberg F, Ignacio R, et al. Noncancer pain conditions and risk of suicide. *JAMA Psychiatry*. 2013; 70:692–697. [PubMed: 23699975]
13. Singhal A, Ross J, Seminog O, Hawton K, Goldacre M. Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage. *Journal of the Royal Society of Medicine*. 2014; 107:194–204. [PubMed: 24526464]
14. Friedman LE, Gelaye B, Rondon MB, Sanchez SE, Peterlin BL, Williams MA. Association of Migraine Headaches With Suicidal Ideation Among Pregnant Women in Lima, Peru. *Headache*. 2016; 56:741–749. [PubMed: 27016264]
15. Wang S, Fuh J, Juang K, Lu S. Migraine and suicidal ideation in adolescents aged 13 to 15 years. *Neurology*. 2009; 72:1146–1152. [PubMed: 19332691]
16. Wang S, Juang K, Fuh J, Lu S. Psychiatric comorbidity and suicide risk in adolescents with chronic daily headache. *Neurology*. 2007; 68:1468–1473. [PubMed: 17470748]
17. Fuller-Thomson E, Hamelin G, Granger S. Suicidal ideation in a population-based sample of adolescents: implications for family medicine practice. *ISRN Family Medicine*. 2013; 2013:282378. [PubMed: 24967322]
18. Breslau N. Migraine, suicidal ideation, and suicide attempts. *Neurology*. 1992; 42:392–395. [PubMed: 1736172]
19. (HCUP) HCaUP. Introduction to the HCUP National Inpatient Sample (NIS). 2015 In;
20. (HCUP) HCaUP. Introduction to the HCUP Nationwide Inpatient Sample (NIS). 2015 In;
21. Lin KH, Chen YT, Fuh JL, et al. Migraine is associated with a higher risk of transient global amnesia: a nationwide cohort study. *Eur J Neurol*. 2014; 21:718–724. [PubMed: 24520813]
22. Dietz P, Williams S, Callaghan W, Bachman D, Whitlock E, MC MH. Clinically identified maternal depression before, during, and after pregnancies ending in live births. *Am J Psychiatry*. 2007; 164:1515–1520. [PubMed: 17898342]
23. Minneapolis FRBo. Consumer Price Index, 1913– 2015 In;
24. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. *J Clin Epidemiol*. 2008; 61:1234–1240. [PubMed: 18619805]
25. Charlson M, Szatrowski T, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol*. 1994; 47:1245–1251. [PubMed: 7722560]
26. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005; 43:1130–1139. [PubMed: 16224307]
27. Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. *Neurologic Clinics*. 2009; 27:321–334. [PubMed: 19289218]
28. Finocchi C, Strada L. Sex-related differences in migraine. *Neurological Sciences*. 2014; 35(Suppl 1):207–213. [PubMed: 24867868]
29. Breslau N, Schultz L, Lipton R, Peterson E, Welch K. Migraine headaches and suicide attempt. *Headache*. 2012; 52:723–731. [PubMed: 22404176]
30. Moon J, Smith J, Lahr B, Cutrer F. Longitudinal Associations of Migraine and Depressive Symptoms: A Cohort Analysis. *Psychosomatics*. 2013; 54:317–327. [PubMed: 23274003]
31. Lanteri-Minet M, Radat F, Chautard MH, Lucas C. Anxiety and depression associated with migraine: influence on migraine subjects' disability and quality of life, and acute migraine management. *Pain*. 2005; 118:319–326. [PubMed: 16289799]
32. Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. *Neuropsychobiology*. 2004; 50:322–328. [PubMed: 15539864]

33. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. *Headache*. 2006; 46:1334–1343. [PubMed: 17040331]
34. Nicholson R, Houle T, Rhudy J, Norton P, Montagna P. Psychological Risk Factors in Headache. *Headache*. 2007; 47:413–426. [PubMed: 17371358]
35. Stuginski-Barbosa J, Dach F, Bigal M, Speciali JG. Chronic pain and depression in the quality of life of women with migraine--a controlled study. *Headache*. 2012; 52:400–408. [PubMed: 22332812]
36. Ligthart L, Hottenga JJ, Lewis CM, et al. Genetic risk score analysis indicates migraine with and without comorbid depression are genetically different disorders. *Hum Genet*. 2014; 133:173–186. [PubMed: 24081561]
37. Ashina S, Serrano D, Lipton R, et al. Depression and risk of transformation of episodic to chronic migraine. *J Headache Pain*. 2012; 13:615–624. [PubMed: 23007859]
38. Hung CI, Liu CY, Yang CH, Wang SJ. The Impacts of Migraine among Outpatients with Major Depressive Disorder at a Two-Year Follow-Up. *PLoS One*. 2015; 10:e0128087. [PubMed: 26000962]
39. White, E., Armstrong, BK., Saracci, R. *Principles of Exposure Measurement in Epidemiology: Collecting, Evaluating and Improving Measures of Disease Risk Factors*. 2. Oxford University Press; 2008.
40. Gelfand AA, Fullerton HJ, Jacobson A, et al. Is migraine a risk factor for pediatric stroke? *Cephalalgia*. 2015; 35:1252–1260. [PubMed: 25754176]
41. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). *Cephalalgia*. 2011; 31:301–315. [PubMed: 20813784]
42. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). *Headache*. 2011; 51:1058–1077. [PubMed: 21762134]
43. Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). *J Headache Pain*. 2012; 13:361–378. [PubMed: 22644214]
44. Calati R, Laglaoui Bakhiyi C, Artero S, Ilgen M, Courtet P. The impact of physical pain on suicidal thoughts and behaviors: Meta-analyses. *J Psychiatr Res*. 2015; 71:16–32. [PubMed: 26522868]
45. Liu H, Fuh J, Lin Y, Chen W, Wang S. Suicide risk in patients with migraine and comorbid fibromyalgia. *Neurology*. 2015; 85:1017–1023. [PubMed: 26296516]

**Table 1**  
Baseline characteristics of participants with and without migraine-related hospitalizations (N = 156,172,826)

Characteristics	All participants (N = 156,172,826)		With migraine (N = 2,190,305)		Without migraine (N = 153,982,521)		P-value
	N	%	N	%	N	%	
<b>Demographics</b>							
Age, mean (SE), years	57.2 (0.1)		47.0 (0.1)		57.3 (0.1)		<0.0001
Age categories, years							
< 50	56,578,582	36.2	1,269,024	57.9	55,309,559	35.9	<0.0001
50	99,594,244	63.7	921,281	42.1	98,672,963	64.1	
<b>Sex</b>							
Male	62,465,446	40.0	373,006	17.0	62,092,440	40.3	<0.0001
Female	93,512,367	59.9	1,816,284	82.9	91,696,083	59.5	
<b>Race</b>							
White	89,598,207	57.4	1,395,081	63.7	88,203,126	57.3	<0.0001
Black	18,675,063	12.0	213,962	9.8	18,461,101	12.0	
Hispanic	13,908,300	8.9	143,848	6.6	13,764,452	8.9	
Asian or Pacific Islander	3,120,840	2.0	19,929	0.9	3,100,910	2.0	
Native American	922,436	0.6	10,739	0.5	911,697	0.6	
Other	4,022,803	2.6	41,305	1.9	3,981,498	2.6	
Missing	25,925,177	16.6	365,440	16.7	25,559,736	16.6	
<b>Median household income quartiles for patient zip code</b>							
Quartile 1 (poorest)	44,037,915	28.2	534,928	24.4	43,502,988	28.3	<0.0001
Quartile 2	39,654,825	25.4	547,897	25.0	39,106,927	25.4	
Quartile 3	36,250,515	23.2	550,247	25.1	35,700,268	23.2	
Quartile 4 (wealthiest)	32,217,473	20.6	509,402	23.3	31,708,071	20.6	
Missing	4,012,098	2.6	47,830	2.2	3,964,268	2.6	
<b>Smoking</b>	20,570,488	13.2	416,147	19.0	20,154,342	13.1	<0.0001
<b>Length of stay, mean (SE), day</b>	4.7 (0.02)		3.9 (0.03)		4.7 (0.02)		<0.0001
<b>Psychiatric Characteristics</b>							

Characteristics	All participants (N = 156,172,826)		With migraine (N = 2,190,305)		Without migraine (N = 153,982,521)		P-value
	N	%	N	%	N	%	
<b>Non-psychotic depression</b>	17,961,784	11.5	611,861	27.9	17,349,923	11.3	<0.0001
<b>PTSD</b>	840,338	0.54	54,429	2.4	785,909	0.51	<0.0001
<b>Anxiety</b>	7,670,389	4.9	276,417	12.6	7,393,972	4.8	<0.0001
<b>Alcohol or substance abuse</b>	27,493,377	17.6	532,712	24.3	26,960,665	17.5	<0.0001
<b>Psychosis</b>	11,106,021	7.1	325,802	14.9	10,780,219	7.0	<0.0001
<b>Any psychiatric disorder</b>	48,238,790	30.9	1,164,806	53.2	47,073,984	30.6	<0.0001
<b>Age-adjusted Charlson Comorbidity Index</b>							
0	40,306,974	25.8	757,824	34.6	39,549,150	25.7	<0.0001
1	16,262,416	10.4	532,438	24.3	15,729,978	10.2	
2	99,603,436	63.8	900,042	41.1	98,703,393	64.1	

Rounded components may not add up to the rounded sum due to weighting and rounding.  
 Percentages may not add up to 100% due to rounding, or missing data.

Abbreviations: SE, standard error; PTSD, Posttraumatic stress disorder

**Table 2**

Association between migraine and suicidal behaviors by psychiatric disorder status (N = 156,172,826)

Suicidal behaviors	With migraine (N = 2,190,305)	Without migraine (N = 153,982,521)	OR (95% CI)	
			Unadjusted	Adjusted <sup>a</sup>
No suicidal behavior	2,097,808	151,505,167	Reference	Reference
Suicidal behavior	92,497	2,477,354	2.69 (2.55, 2.86)	2.07 (1.96, 2.19)
<b>Stratified by depression</b>				
With depression (N = 17,961,785)				
No suicidal behavior	556,429	15,962,426	Reference	Reference
Suicidal behavior	55,433	1,387,497	1.15 (1.08, 1.21)	0.80 (0.76, 0.85)
Without depression (N = 138,211,041)				
No suicidal behavior	1,541,379	135,542,741	Reference	Reference
Suicidal behavior	37,064	1,089,857	2.99 (2.80, 3.20)	2.35 (2.20, 2.51)
<b>Stratified by anxiety</b>				
With anxiety (N = 7,670,390)				
No suicidal behavior	255,719	7,061,486	Reference	Reference
Suicidal behavior	20,698	332,487	1.72 (1.63, 1.82)	1.07 (1.02, 1.13)
Without anxiety (N = 148,502,437)				
No suicidal behavior	1,842,089	144,443,681	Reference	Reference
Suicidal behavior	71,799	2,144,868	2.63 (2.46, 2.80)	2.06 (1.94, 2.20)
<b>Stratified by PTSD</b>				
With PTSD (N = 840,339)				
No suicidal behavior	40,500	608,209	Reference	Reference
Suicidal behavior	13,929	177,701	1.18 (1.11, 1.25)	1.00 (0.94, 1.07)
Without PTSD (N = 155,332,488)				
No suicidal behavior	2,057,308	150,896,959	Reference	Reference
Suicidal behavior	78,568	2,299,653	2.51 (2.36, 2.67)	1.95 (1.84, 2.08)

Individual cell counts may not add up to the global cell counts because of rounding and the differences arising from variance computations when using the discharge weights. Percentages may not add up to 100% due to rounding, missing data, or data falling into categories too small to report.

Abbreviations: OR, odds ratio; CI, confidence interval; PTSD, Posttraumatic stress disorder

<sup>a</sup>Adjusted for age (continuous), sex, race, median household income quartiles for patient zip code, hospital location, hospital region, year, and age-adjusted Charlson Comorbidity Index.